RNF128通过稳定SCD1加重代谢功能障碍相关脂肪性肝病进展
研究利用bulk RNA-seq和高脂高胆固醇饮食诱导的MASLD小鼠模型,发现E3泛素连接酶RNF128在人类MASLD肝脏和小鼠模型中上调;肝细胞特异性敲除RNF128可改善MASLD,而过表达则加重病情。机制上RNF128催化SCD1第30位赖氨酸K63连接泛素化,阻断其自噬-溶酶体降解从而稳定SCD1,促进脂质积累;靶向抑制RNF128(GalNAc-ASO或shRNA-AAV)可缓解小鼠MASLD。
要点
- RNF128在人类MASLD肝脏和高脂高胆固醇饮食小鼠中表达上调。
- 肝细胞RNF128敲除改善MASLD,过表达加重疾病表型。
- RNF128通过K63泛素化稳定SCD1促进脂质积累,抑制SCD1可挽救。
核心结论
- RNF128-SCD1轴是MASLD的核心机制,具有治疗潜力。
研究设计与样本
- 采用bulk RNA-seq和高脂高胆固醇饮食诱导的MASLD小鼠模型探索RNF128表达模式。
- 利用单细胞RNA测序和脂毒性诱导的肝细胞模型表征肝脏RNF128表达。
- 评估肝细胞特异性RNF128缺失和过表达对MASLD进展的影响,并研究分子机制及化学和遗传干预的治疗潜力。
主要发现
- E3泛素连接酶RNF128在人类MASLD肝脏和高脂高胆固醇饮食小鼠中上调。
- 肝细胞特异性RNF128敲除改善MASLD,而过表达加剧疾病表型。
- RNF128催化SCD1第30位赖氨酸K63连接泛素化,阻断其自噬-溶酶体降解而稳定SCD1,促进脂质积累。
- SCD1过表达逆转RNF128缺失效应,SCD1抑制在肝细胞和体内挽救RNF128驱动的脂肪变性。
临床怎么用
- 靶向抑制RNF128(GalNAc偶联反义寡核苷酸或肝细胞特异性TBG启动子驱动的shRNA-AAV)可缓解小鼠MASLD。
- 抑制SCD1可挽救RNF128驱动的脂肪变性,提示SCD1为潜在干预节点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) progresses from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), yet its therapeutic development has been hampered by pathological complexity and heterogeneity. APPROACH RESULTS: Bulk RNA-seq and diet-induced MASLD mouse models were employed to explore RNF128 expression patterns in MASLD livers. Hepatic RNF128 expression was characterized in single-cell RNA sequencing (scRNA-seq) and lipotoxicity-induced hepatocyte models. The impact of hepatocyte-specific RNF128 deletion and overexpression on MASLD progression was evaluated. Furthermore, the molecular mechanisms through which RNF128 exerts its functions were investigated, and both chemical and genetic approaches were employed to assess its potential as a therapeutic target.We found that the E3 ubiquitin ligase RNF128 is upregulated in human MASLD livers and in mice fed a high-fat, high-cholesterol diet. Hepatocyte-specific RNF128 knockout ameliorated MASLD, whereas its overexpression exacerbated disease phenotypes. Integrated proteomic and ubiquitinomic analyses identified stearoyl-CoA desaturase 1 (SCD1) as a direct target of RNF128. Mechanistically, RNF128 catalyzes K63-linked ubiquitination of SCD1 at lysine 30, which stabilizes SCD1 by blocking its autophagic-lysosomal degradation, thereby promoting lipid accumulation. Crucially, SCD1 overexpression reversed the effects of RNF128 loss, and SCD1 inhibition rescued RNF128-driven steatosis, both in hepatocytes and in vivo. Therapeutic inhibition of RNF128 with a GalNAc-conjugated antisense oligonucleotide (GalNAc-ASO) and a hepatocyte-specific TBG-promoter-driven shRNA-AAV alleviated MASLD in mice. CONCLUSIONS: Our study establishes the RNF128-SCD1 axis as a central mechanism in MASLD and highlights its therapeutic potential.
引用
- Cao L, Yang W, Wang C, et al. RNF128 aggravates metabolic dysfunction-associated steatotic liver disease progression via stabilization of SCD1. Hepatology. 2026. PMID: 41911552. doi:10.1097/HEP.0000000000001757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。